- SEK27.86bn
- SEK25.86bn
- SEK2.00bn
Brief: BioArctic Says Sales Of Leqembi Reached EUR 200 Million In Eisai FY 2024
Brief: Bioarctic Proposes No Dividend For FY 2024
Brief: BioArctic Q4 Operating Profit SEK -53.5 Million
Brief: BioArctic Says Sales Of Leqembi Totaled 13.3 Bln Yen In Q4 2024
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
Brief: Bioarctic Says FDA Accepts Biologics License Application For Subcutaneous Maintenance Dosing Of Leqembi In US
Brief: Bioarctic Announces Global License Agreement For Antibody Program
Brief: Bioarctic AB Says Leqembi Approved In Mexico
Brief: Leqembi Launched In South Korea
RBC ups BioArctic TP after CHMP's Alzheimer's drug recommendation
Europe Research Roundup: Imperial Brands, Morgan Sindall, WH Smith
Brief: BioArctic Says CHMP Issues Positive Recommendation For Approval Of Lecanemab In The EU
Brief: BioArctic Q3 Operating Profit SEK -26.1 Million
Brief: Bioarctic AB Says Eisai Expects Leqembi Sales To Reach JPY 42.5 Billion for FY.
Brief: Eisai Completes Rolling BLA Submission For Subcutaneous Maintenance Dosing Of Leqembi® (Lecanemab-Irmb) In The Us
Brief: Leqembi® Q3 Revenue Totaled Jpy 10 Billion
Brief: Eisai Will Request Reconsideration Of Initial Decision For Lecanemab In Australia
Brief: BioArctic Q2 Operating Profit SEK -75.8 Million
Brief: BioArctic Study Results From Phase 1 Studies With Exidavnemab